Search

Hydrogenated soybean oil

It may be found in cosmetics and personal care products as an emollient or skin conditioning agent. … According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance.

RTP-801i

The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

Mevastatin

It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. … It has served as one of the lead compounds for the development of the synthetic compounds used today.

SW033291

[A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]

Xylazine

[A9095,L42675,A251420] It acts as an agonist at α2 adrenoceptors; however, its affinity is lower than the one reported for other α2 adrenergic receptor agonists such as [detomidine] and [medetomidine]. … [L42675] Xylazine is sometimes used as an adulterant and combined with opioids and recreational drugs; however, it has no antidote, and the use of [naloxone] has no effect on xylazine.[L42675,L42680]

Chromic citrate

Reslizumab

It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. … It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe.

Inositol 1,3-bisphosphate

It has molecular formula C6H14O12P2 and is categorized as a sugar phosphate/sugar alcohol. … The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural

Amilomotide

It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.

Reposal

Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.